Crypto firm Tether to further reduce holdings of commercial debt in stablecoin reserves

Crypto firm Tether to further reduce holdings of commercial debt in stablecoin reserves


PARIS — Crypto firm Tether is planning to reduce its holdings of commercial debt in its reserves, as the issuer of the world’s most-used “stablecoin” continues to face questions about what its digital currency is actually backed by.

Last year, Tether revealed that it held some cash but also bought a large amount of commercial paper, which is short-term corporate debt. This raised concerns given that Tether does not disclose exactly which companies it holds commercial paper from, and where those entities are based.

But the company has been reducing the amount of commercial paper in its reserves. In the fourth quarter of 2021, commercial paper made up just over 30% of Tether’s total reserves, down from more than 44% in the third quarter.

“Over time we will keep reducing the commercial paper, we aren’t finished yet with the reduction,” Paolo Ardoino, chief technology officer of Tether and affiliated cryptocurrency exchange Bitfinex, told CNBC on Wednesday at the Paris Blockchain Week Summit.

Ardoino said Tether has moved the money from this commercial paper to U.S. Treasurys.

A stablecoin is a type of digital currency designed to be pegged to a real world asset such as the U.S. dollar. Their value is not supposed to fluctuate that much, unlike the wild swings seen in cryptocurrencies like bitcoin.

Tether issues the USDT token and its market capitalization sits at more than $82 billion. Crypto traders use USDT to trade in an out of cryptocurrencies like bitcoin rather than swapping their money into the fiat version of the U.S. dollar.

But there has been controversy over claims made by Tether and its reserves. Last year, the U.S. Commodity Futures Trading Commission fined Tether $41 million for “making untrue or misleading statements” that its USDT token was backed 100% by corresponding fiat currencies.

Last year, as part of a settlement with the New York Attorney General over a separate case, Tether agreed to provide a breakdown of the assets backing its digital currency.

But it has not disclosed the companies whose commercial paper it owns. Tether does disclose the quality ratings of the debt it owns, however.

Ardoino pledged further transparency but did not specify what else the company may disclose.

“Our journey towards increased transparency is not finished yet,” Ardoino said.



Source

Judge dismisses Trump defamation lawsuit against Murdoch, WSJ about Epstein letter
World

Judge dismisses Trump defamation lawsuit against Murdoch, WSJ about Epstein letter

U.S. President Donald Trump and Rupert Murdoch. Julia Demaree Nikhinson | Jonathan Ernst | Reuters A federal judge in Florida on Monday dismissed President Donald Trump’s $10 billion lawsuit against media baron Rupert Murdoch and The Wall Street Journal, which claimed the newspaper defamed Trump with a story saying the president had sent a “bawdy” […]

Read More
Dollar strengthens as Iran talks break down — Two reasons why HSBC says the greenback is set to soften
World

Dollar strengthens as Iran talks break down — Two reasons why HSBC says the greenback is set to soften

The U.S. dollar rose on Monday after talks between Washington and Tehran over the weekend failed to yield an agreement to end the war. The greenback rose 0.3% against the Euro to $1.169 and 0.25% against sterling to $1.342 after peace talks broke down and President Trump said the U.S. military would begin a blockade […]

Read More
Revolution Medicines’ potential breakthrough pancreatic cancer drug succeeds in late-stage trial
World

Revolution Medicines’ potential breakthrough pancreatic cancer drug succeeds in late-stage trial

Pancreatic cancer, illustration Nemes Laszl | Science Photo Library | Getty Images Revolution Medicines‘ drug for pancreatic cancer succeeded in a highly anticipated Phase 3 trial, almost doubling the typical length of survival and slashing the risk of death by 60% versus chemotherapy, the company said Monday. RevMed said its daily pill, daraxonrasib, met all […]

Read More